Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
12 Août 2024 - 10:51PM
Edgar (US Regulatory)
Free Writing Prospectus
Filed Pursuant to Rule 433
Registration Statement No. 333-262943
Dated August 12, 2024
Eli Lilly and Company
$5,000,000,000 aggregate principal amount of Notes offered
Pricing Term Sheet
4.150%
Notes due 2027 (the “2027 Notes”)
4.200% Notes due 2029 (the “2029 Notes”)
4.600% Notes due 2034 (the “2034 Notes”)
5.050% Notes due 2054 (the “2054 Notes”)
5.200% Notes due 2064 (the “2064 Notes”)
(collectively, the “Notes”)
|
|
|
| Issuer: |
|
Eli Lilly and Company |
|
|
| Trade Date: |
|
August 12, 2024 |
|
|
| Ratings:* |
|
A1 (Positive outlook) Moody’s A+ (Stable
outlook) S&P |
|
|
| Settlement Date:** |
|
T+2; August 14, 2024 |
|
|
| Joint Book-Running Managers: |
|
BNP Paribas Securities Corp. Citigroup Global
Markets Inc.
Goldman Sachs & Co. LLC J.P. Morgan Securities LLC
Morgan Stanley & Co. LLC |
|
|
| Co-Managers: |
|
Academy Securities, Inc. Loop Capital Markets
LLC Penserra Securities LLC R. Seelaus & Co.,
LLC AmeriVet Securities, Inc. CastleOak Securities, L.P.
CAVU Securities LLC C.L. King & Associates, Inc.
Siebert Williams Shank & Co., LLC |
|
|
| The 2027 Notes |
|
|
|
|
| Principal Amount Offered: |
|
$750,000,000 |
|
|
| Maturity Date: |
|
August 14, 2027 |
|
|
| Coupon: |
|
4.150% per year |
|
|
|
| Public Offering Price: |
|
99.919% of principal amount, plus accrued interest, if any, from August 14, 2024 |
|
|
| Yield to Maturity: |
|
4.179% |
|
|
| Benchmark Treasury: |
|
UST 3.750% due August 15, 2027 |
|
|
| Spread to Benchmark Treasury: |
|
T + 35 basis points |
|
|
| Benchmark Treasury Price and Yield: |
|
99-24 7⁄8 / 3.829% |
|
|
| Interest Payment Dates: |
|
February 14 and August 14, commencing February 14, 2025 |
|
|
| Redemption Provisions: |
|
|
|
|
| Make-whole call: |
|
At any time prior to July 14, 2027 at a discount rate of Treasury plus 7 basis points |
|
|
| Par call: |
|
On or after July 14, 2027 at 100% |
|
|
| CUSIP / ISIN: |
|
532457 CP1 / US532457CP17 |
|
|
| The 2029 Notes |
|
|
|
|
| Principal Amount Offered: |
|
$1,000,000,000 |
|
|
| Maturity Date: |
|
August 14, 2029 |
|
|
| Coupon: |
|
4.200% per year |
|
|
| Public Offering Price: |
|
99.781% of principal amount, plus accrued interest, if any, from August 14, 2024 |
|
|
| Yield to Maturity: |
|
4.249% |
|
|
| Benchmark Treasury: |
|
UST 4.000% due July 31, 2029 |
|
|
| Spread to Benchmark Treasury: |
|
T + 50 basis points |
|
|
| Benchmark Treasury Price and Yield: |
|
101-04 / 3.749% |
|
|
| Interest Payment Dates: |
|
February 14 and August 14, commencing February 14, 2025 |
|
|
| Redemption Provisions: |
|
|
|
|
| Make-whole call: |
|
At any time prior to July 14, 2029 at a discount rate of Treasury plus 10 basis points |
|
|
| Par call: |
|
On or after July 14, 2029 at 100% |
|
|
| CUSIP / ISIN: |
|
532457 CQ9 / US532457CQ99 |
|
|
| The 2034 Notes |
|
|
|
|
| Principal Amount Offered: |
|
$1,250,000,000 |
|
|
| Maturity Date: |
|
August 14, 2034 |
|
|
| Coupon: |
|
4.600% per year |
2
|
|
|
| Public Offering Price: |
|
99.968% of principal amount, plus accrued interest, if any, from August 14, 2024 |
|
|
| Yield to Maturity: |
|
4.604% |
|
|
| Benchmark Treasury: |
|
UST 3.875% due August 15, 2034 |
|
|
| Spread to Benchmark Treasury: |
|
T + 70 basis points |
|
|
| Benchmark Treasury Price and Yield: |
|
99-24+ / 3.904% |
|
|
| Interest Payment Dates: |
|
February 14 and August 14, commencing February 14, 2025 |
|
|
| Redemption Provisions: |
|
|
|
|
| Make-whole call: |
|
At any time prior to May 14, 2034 at a discount rate of Treasury plus 12 basis points |
|
|
| Par call: |
|
On or after May 14, 2034 at 100% |
|
|
| CUSIP / ISIN: |
|
532457 CR7 / US532457CR72 |
|
|
| The 2054 Notes |
|
|
|
|
| Principal Amount Offered: |
|
$1,250,000,000 |
|
|
| Maturity Date: |
|
August 14, 2054 |
|
|
| Coupon: |
|
5.050% per year |
|
|
| Public Offering Price: |
|
99.510% of principal amount, plus accrued interest, if any, from August 14, 2024 |
|
|
| Yield to Maturity: |
|
5.082% |
|
|
| Benchmark Treasury: |
|
UST 4.625% due May 15, 2054 |
|
|
| Spread to Benchmark Treasury: |
|
T + 88 basis points |
|
|
| Benchmark Treasury Price and Yield: |
|
107-04+ / 4.202% |
|
|
| Interest Payment Dates: |
|
February 14 and August 14, commencing February 14, 2025 |
|
|
| Redemption Provisions: |
|
|
|
|
| Make-whole call: |
|
At any time prior to February 14, 2054 at a discount rate of Treasury plus 15 basis points |
|
|
| Par call: |
|
On or after February 14, 2054 at 100% |
|
|
| CUSIP / ISIN: |
|
532457 CS5 / US532457CS55 |
|
|
| The 2064 Notes |
|
|
|
|
| Principal Amount Offered: |
|
$750,000,000 |
|
|
| Maturity Date: |
|
August 14, 2064 |
|
|
| Coupon: |
|
5.200% per year |
|
|
| Public Offering Price: |
|
99.966% of principal amount, plus accrued interest, if any, from August 14, 2024 |
3
|
|
|
| Yield to Maturity: |
|
5.202% |
|
|
| Benchmark Treasury: |
|
UST 4.625% due May 15, 2054 |
|
|
| Spread to Benchmark Treasury: |
|
T + 100 basis points |
|
|
| Benchmark Treasury Price and Yield: |
|
107-04+ / 4.202% |
|
|
| Interest Payment Dates: |
|
February 14 and August 14, commencing February 14, 2025 |
|
|
| Redemption Provisions: |
|
|
|
|
| Make-whole call: |
|
At any time prior to February 14, 2064 at a discount rate of Treasury plus 15 basis points |
|
|
| Par call: |
|
On or after February 14, 2064 at 100% |
|
|
| CUSIP / ISIN: |
|
532457 CT3 / US532457CT39 |
| * |
A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or
withdrawal at any time. |
| ** |
Under Rule 15c6-1 under the Securities Exchange Act of 1934, as
amended, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to one business day before delivery will be
required, by virtue of the fact that the Notes initially will settle in T+2, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own advisors. |
The Issuer has filed a registration statement (No. 333-262943) (including a prospectus) with the
Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus relating to this offering and
the other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, the Issuer, any
underwriter or any dealer participating in the offering will arrange to send you the prospectus and the prospectus supplement if you request it by calling BNP Paribas Securities Corp. at +1-800-854-5674, Citigroup Global Markets Inc. at
+1-800-831-9146, Goldman Sachs & Co. LLC at +1-866-471-2526, J.P. Morgan Securities LLC at +1 212-834-4533 or Morgan
Stanley & Co. LLC at +1-866-718-1649.
ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS
OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.
4
Eli Lilly (NYSE:LLY)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Eli Lilly (NYSE:LLY)
Graphique Historique de l'Action
De Août 2023 à Août 2024
